Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.

Tian W, Ding W, Kim S, Zheng L, Zhang L, Li X, Gu J, Zhang L, Pan M, Chen S.

PLoS One. 2013 Jul 4;8(7):e67929. doi: 10.1371/journal.pone.0067929. Print 2013.

PMID:
23861835
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.

Qi WX, Tang LN, He AN, Shen Z, Yao Y.

Lung. 2011 Dec;189(6):437-43. doi: 10.1007/s00408-011-9332-1. Epub 2011 Oct 11.

PMID:
21986852
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Zhang X, Qin Y, Li H, Bai C, Zhu T, Xu J, Wu C, Wu M, Wang C, Song H, Wei L, He J.

Asian Pac J Cancer Prev. 2011;12(11):2857-63. Review.

PMID:
22393954
[PubMed - indexed for MEDLINE]
Free Article
4.

Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

Pan G, Ke S, Zhao J.

Target Oncol. 2013 Jun;8(2):107-16. doi: 10.1007/s11523-013-0272-y. Epub 2013 Mar 21. Review.

PMID:
23516098
[PubMed - indexed for MEDLINE]
5.

Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.

Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Shi Y, Song Y.

Clin Oncol (R Coll Radiol). 2013 Jan;25(1):e7-e15. doi: 10.1016/j.clon.2012.09.005. Epub 2012 Nov 21.

PMID:
23177099
[PubMed - indexed for MEDLINE]
6.

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD.

J Clin Oncol. 2011 Mar 10;29(8):1059-66. doi: 10.1200/JCO.2010.28.5981. Epub 2011 Jan 31.

PMID:
21282542
[PubMed - indexed for MEDLINE]
Free Article
7.

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.

Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y, Shi Y.

Eur J Clin Pharmacol. 2013 Feb;69(2):151-9. doi: 10.1007/s00228-012-1333-3. Epub 2012 Jun 24.

PMID:
22729611
[PubMed - indexed for MEDLINE]
8.

[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].

Tao L, Zhuo W, Yang F, Zhu B.

Zhongguo Fei Ai Za Zhi. 2012 Mar;15(3):172-8. doi: 10.3779/j.issn.1009-3419.2012.03.07. Chinese.

PMID:
22429581
[PubMed - indexed for MEDLINE]
Free Article
9.

Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.

Wu X, Jin Y, Cui IH, Xu Z, Zhang Y, Zhang X, Tang C, Gong Y, Chen J.

Anticancer Drugs. 2012 Aug;23(7):731-8. doi: 10.1097/CAD.0b013e32835514f4.

PMID:
22700001
[PubMed - indexed for MEDLINE]
10.

Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y.

Lung. 2012 Oct;190(5):477-85. Epub 2012 Jun 19. Review.

PMID:
22711060
[PubMed - indexed for MEDLINE]
11.

Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.

Botrel TE, Clark O, Clark L, Paladini L, Faleiros E, Pegoretti B.

Lung Cancer. 2011 Oct;74(1):89-97. doi: 10.1016/j.lungcan.2011.01.028. Epub 2011 Mar 5. Review.

PMID:
21377753
[PubMed - indexed for MEDLINE]
12.

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).

Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH.

J Thorac Oncol. 2013 Aug;8(8):1075-83. doi: 10.1097/JTO.0b013e3182937317.

PMID:
23689430
[PubMed - indexed for MEDLINE]
13.

Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.

Lima AB, Macedo LT, Sasse AD.

PLoS One. 2011;6(8):e22681. doi: 10.1371/journal.pone.0022681. Epub 2011 Aug 2. Review.

PMID:
21829644
[PubMed - indexed for MEDLINE]
Free PMC Article
14.
15.

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV.

Clin Cancer Res. 2009 May 15;15(10):3600-9. doi: 10.1158/1078-0432.CCR-08-2568. Epub 2009 May 15.

PMID:
19447868
[PubMed - indexed for MEDLINE]
Free Article
16.

Vandetanib: An overview of its clinical development in NSCLC and other tumors.

Morabito A, Piccirillo MC, Costanzo R, Sandomenico C, Carillio G, Daniele G, Giordano P, Bryce J, Carotenuto P, La Rocca A, Di Maio M, Normanno N, Rocco G, Perrone F.

Drugs Today (Barc). 2010 Sep;46(9):683-98. doi: 10.1358/dot.2010.46.9.1516989. Review.

PMID:
20967300
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.

Tian W, Ding W, Kim S, Xu X, Pan M, Chen S.

Pancreatology. 2013 Jul-Aug;13(4):415-22. doi: 10.1016/j.pan.2013.04.195. Epub 2013 Apr 28.

PMID:
23890141
[PubMed - indexed for MEDLINE]
18.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M.

J Clin Oncol. 2009 May 20;27(15):2523-9. doi: 10.1200/JCO.2008.18.6015. Epub 2009 Mar 30.

PMID:
19332730
[PubMed - indexed for MEDLINE]
Free Article
19.

Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.

Zhou H, Zeng C, Wang LY, Xie H, Zhou J, Diao P, Yao WX, Zhao X, Wei Y.

Chin Med J (Engl). 2013;126(17):3348-55.

PMID:
24033963
[PubMed - indexed for MEDLINE]
Free Article
20.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC.

J Natl Cancer Inst. 2013 May 1;105(9):595-605. doi: 10.1093/jnci/djt072. Epub 2013 Apr 17. Review.

PMID:
23594426
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk